PAT may be best understood as a specialty mental health intervention embedded in collaborative care.

Referral pathways mirror a familiar primary-care-to-specialist model used across medicine and psychology.

PAT can help patients become more emotionally flexible and engaged in ongoing therapy.

Ideal integration depends on continuity, communication, and returning patients to their primary providers.

As mental health care continues to evolve, psychedelic treatments have been moving into regulated clinical research with the potential for approval by regulatory bodies in the near future. Molecules such as psilocybin, MDMA, DMT, and LSD analogs are now being studied in FDA-approved trials for conditions including depression, PTSD, adjustment disorder, and anxiety-related disorders. As the treatments progress through clinical research and towards the potential for FDA approval in the near future, it is important to consider how the treatments may fit into existing mental health treatment approaches and systems.

Many clinicians may be aware of the potential to refer their patients to a psychedelic research trial but, for a multitude of reasons, may be unsure whether this is the right path. For many referring clinicians, interest is paired with uncertainty: How does this treatment fit with traditional care? Does psychedelic treatment replace other therapies? Compete with medication management? Or disrupt established treatment relationships?

There is a gap in education for providers who may be interested in referring clients to a psychedelic research trial but don’t know what to expect or how to get information regarding a patient’s eligibility.

In practice, psychedelic clinical trials can fit well as specialty interventions embedded within collaborative clinical models. Psychedelic treatments may work best alongside ongoing psychological or psychiatric care, similar to how primary care providers refer patients to cardiology, neurology, or pain specialists while remaining the patient’s primary provider. Rather than pulling patients away from their existing providers, effective psychedelic treatment models will aim to strengthen the continuum of care.

Most clinicians already work within referral ecosystems. A primary care clinician does not treat every medical condition alone; instead, they coordinate with specialists while maintaining responsibility for the patient’s overall health.

Psychedelic treatments can function similarly. These intensive treatments offer a time-limited, protocol-driven, targeted intervention, designed to........

© Psychology Today